Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Gajewski JL, et al. Biol Blood Marrow Transplant. 2002;8(10):550-6. doi: 10.1053/bbmt.2002.v8.pm12434950. Biol Blood Marrow Transplant. 2002. PMID: 12434950 Free article. Clinical Trial.
Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
Montemurro F, Rondón G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Montemurro F, et al. Among authors: gajewski jl. Biol Blood Marrow Transplant. 2003 May;9(5):330-40. doi: 10.1016/s1083-8791(03)00088-0. Biol Blood Marrow Transplant. 2003. PMID: 12766883 Free article.
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Ueno NT, et al. Among authors: gajewski jl. Blood. 2003 Nov 15;102(10):3829-36. doi: 10.1182/blood-2003-04-1022. Epub 2003 Jul 24. Blood. 2003. PMID: 12881308 Free article. Clinical Trial.
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. Cheng YC, et al. Among authors: gajewski jl. Biol Blood Marrow Transplant. 2004 Nov;10(11):794-804. doi: 10.1016/j.bbmt.2004.07.009. Biol Blood Marrow Transplant. 2004. PMID: 15505610 Free article. Clinical Trial.
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Couriel DR, et al. Biol Blood Marrow Transplant. 2004 Mar;10(3):178-85. doi: 10.1016/j.bbmt.2003.10.006. Biol Blood Marrow Transplant. 2004. PMID: 14993883 Free article.
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Wong R, et al. Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14. doi: 10.1016/j.bbmt.2004.10.008. Biol Blood Marrow Transplant. 2005. PMID: 15682071 Free article.
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Andersson BS, et al. Biol Blood Marrow Transplant. 2002;8(9):477-85. doi: 10.1053/bbmt.2002.v8.pm12374452. Biol Blood Marrow Transplant. 2002. PMID: 12374452 Free article. Clinical Trial.
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Ueno NT, et al. Among authors: gajewski jl. J Clin Oncol. 1998 Mar;16(3):986-93. doi: 10.1200/JCO.1998.16.3.986. J Clin Oncol. 1998. PMID: 9508181
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Khouri IF, et al. Among authors: gajewski jl. Blood. 2001 Dec 15;98(13):3595-9. doi: 10.1182/blood.v98.13.3595. Blood. 2001. PMID: 11739162 Free article. Clinical Trial.
Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.
Montemurro F, Rondón G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Montemurro F, et al. Among authors: gajewski jl. Bone Marrow Transplant. 2002 May;29(10):861-6. doi: 10.1038/sj.bmt.1703555. Bone Marrow Transplant. 2002. PMID: 12058236
170 results